Comparison of Toxicity Associated With Early Morning Versus Late Afternoon Radiotherapy in Patients With Head-and-Neck Cancer: A Prospective Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (HN3)

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 1, 2009, Pages 166-172

  Bjarnason, Georg A ^a   MacKenzie, Robert G ^a   Nabid, Abdenour ^b   Hodson, Ian D ^c   El Sayed, Samy ^d   Grimard, Laval ^d   Brundage, Michael ^e   Wright, James ^c   Hay, John ^f   Ganguly, Pradip ^g   Leong, Carson ^h   Wilson, Jane ^f   Jordan, Richard C K ⁱ   Walker, Melanie ^j   Tu, Dongsheng ^j   Parulekar, Wendy ^j  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e Cancer Centre of Southeastern Ontario   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g Dr H Bliss Murphy Cancer Centre   (Canada)

^h Fraser Valley Cancer Centre   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Clinical Trials Group   (Canada)

more..

Author keywords

Cell cycle; Chronoradiotherapy; Circadian rhythm; Head and neck cancer; Radiotherapy

Indexed keywords

ANIMAL CELL CULTURE; PATIENT MONITORING;

CELL CYCLE; CELL CYCLES; CHRONORADIOTHERAPY; CIRCADIAN RHYTHM; CIRCADIAN RHYTHMS; CLINICAL TRIALS; EXPLORATORY ANALYSES; HEAD-AND-NECK CANCER; MUCOSITIS; NATIONAL CANCER INSTITUTES; NECK CANCERS; ORAL MUCOSAS; ORAL MUCOSITIS; PROOF OF PRINCIPLES; RADIATION DOSES; RADIATION THERAPIES; RANDOMIZED TRIALS; SCORING SYSTEMS; SIGNIFICANT REDUCTIONS; WEIGHT LOSSES;

RADIOTHERAPY;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL MUCOSAL DISEASE; ORAL MUCOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CIRCADIAN RHYTHM; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; STOMATITIS; UNITED STATES;

EID: 57649098380     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.07.009     Document Type: Article

References (44)

1. Elting L.S., Cooksley C., Chambers M., et al. The burdens of cancer therapy: Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 (2003) 1531-1539
2. Nguyen N.P., Sallah S., Karlsson U., et al. Combined chemotherapy and radiation therapy for head and neck malignancies: Quality of life issues. Cancer 94 (2002) 1131-1141
3. Rosenthal D.I., Lewin J.S., and Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24 (2006) 2636-2643
4. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 66 (2003) 253-262
5. Epstein J.B., Silverman Jr. S., Paggiarino D.A., et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92 (2001) 875-885
6. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 (2004) 2026-2046
7. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 (2004) 2590-2598
8. Nasilowska-Adamska B., Rzepecki P., Manko J., et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 40 (2007) 983-988
9. Brizel D.M. Pharmacologic approaches to radiation protection. J Clin Oncol 25 (2007) 4084-4089
10. Pignon J.P., le Maitre A., and Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 69 (2007) S112-S114
11. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368 (2006) 843-854
12. Bjarnason G.A., and Jordan R. Rhythms in human gastrointestinal mucosa and skin. Chronobiol Int 19 (2002) 129-140
13. Reppert S.M., and Weaver D.R. Coordination of circadian timing in mammals. Nature 418 (2002) 935-941
14. Hastings M.H., Reddy A.B., and Maywood E.S. A clockwork web: Circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4 (2003) 649-661
15. Kohsaka A., and Bass J. A sense of time: How molecular clocks organize metabolism. Trends Endocrinol Metab 18 (2007) 4-11
16. Fu L., Pelicano H., Liu J., et al. The circadian gene period 2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 (2002) 41-50
17. Matsuo T., Yamaguchi S., Mitsui S., et al. Control mechanism of the circadian clock for timing of cell division in vivo. Science 302 (2003) 255-259
18. Bjarnason G.A., Jordan R.C.K., Wood P.A., et al. Circadian expression of clock genes in human oral mucosa and skin: Association with specific cell cycle phases. Am J Pathol 158 (2001) 1793-1801
19. Bjarnason G.A., Jordan R., and Sothern R.B. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol 154 (1999) 613-622
20. Scheving L.E., Burns E.R., and Pauly J.E. Circadian rhythms and mitotic activity and 3H-thymidine uptake in the duodenum; effect of isoproterenol on the mitotic rhythm. Am J Anat 135 (1972) 311-317
21. Scheving L.E., Burns E.R., Pauly J.E., et al. Circadian variation in cell division of the mouse alimentary tract, bone marrow and corneal epithelium. Anat Rec 191 (1978) 479-486
22. Potten C.S., Booth D., Cragg N.J., et al. Cell kinetic studies in murine ventral tongue epithelium: Cell cycle progression studies using double labelling techniques. Cell Prolif 35 Suppl. 1 (2002) 16-21
23. Buchi K.N., Moore J.G., Hrushesky W.J.M., et al. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterol 101 (1991) 410-415
24. Marra G., Anti M., Percesepe A., et al. Circadian variation of epithelial cell proliferation in human rectal crypts. Gastroenterology 106 (1994) 982-987
25. Tähti E. Studies of the effect of x-irradiation on 24 hour variations in the mitotic activity in human malignant tumours. Acta Pathol Microbiol Scand 117 (1956) 1-61
26. Newsome-Tabatabai R., and Rushton P.S. Daily variation in radiosensitivity of circulating blood cells and bone marrow cellularity of mice. Comp Biochem Physiol 78A (1984) 779-783
27. Rubin N.H. Influence of the circadian rhythm in cell division on radiation-induced mitotic delay in vivo. Radiat Res 89 (1982) 65-76
28. Conannon J.P., Dalbow M.H., Weil C., et al. Radiation and actinomycin D mortality studies: Circadian variations in lethality due to independent effects of either agent. Int J Radiat Biol 24 (1973) 405-411
29. Haus E. Chronobiology of the mammalian response to ionizing radiation. Potential applications in oncology. Chronobiol Int 19 (2002) 77-100
30. Ijiri K., and Potten C.S. The circadian rhythm for the number and sensitivity of radiation-induced apoptosis in the crypts of mouse small intestine. Int J Radiat Biol 58 (1990) 165-175
31. Ijiri K., and Potten C.S. Radiation-hypersensitive cells in small intestinal crypts: Their relationship to clonogenic cells. Br J Cancer 53 (1986) 10-22
32. Ijiri K., and Pottents C.S. Circadian rhythms in the incidence of apoptotic cells and number of clonogenic cells in intestinal crypts after radiation using normal and reversed light conditions. Int J Radiat Biol 53 (1988) 717-727
33. Sinclair W.K., and Morton R.A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29 (1966) 450-474
34. Terasimi T., and Tolmach L.J. Variations in several responses of HeLa cells to X-irradiation during the division cycle. Biophys J 3 (1963) 11-33
35. Hall E.J. Radiosensitivity and cell age in the mitotic cycle. In: Hall E.J. (Ed). Radiobiology for the radiobiologist. 3rd ed. (1988), JB Lippincott, Philadelphia 91-106
36. Sonis S.T., Eilers J.P., Epstein J.B., et al. for the Mucositis Study Group. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 85 (1999) 2103-2113
37. Browman G.P., Wong G., Hodson I., et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328 (1993) 159-163
38. Osoba D., Bezjak A., Brundage M., et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41 (2005) 280-287
39. Brookes G.B. Nutritional status-A prognostic indicator in head and neck cancer. Otolaryngol Head Neck Surg 93 (1985) 69-74
40. Goodwin Jr. W.J., and Torres J. The value of the prognostic nutritional index in the management of patients with advanced carcinoma of the head and neck. Head Neck Surg 6 (1984) 932-937
41. Lin A., Jabbari S., Worden F.P., et al. Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1413-1418
42. Rugg T., Saunders M.I., and Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol 63 (1990) 554-556
43. Stokman M.A., Sonis S.T., Dijkstra P.U., et al. Assessment of oral mucositis in clinical trials: Impact of training on evaluators in a multi-centre trial. Eur J Cancer 41 (2005) 1735-1738
44. Bjarnason G.A., Seth A., Wang Z., et al. Diurnal rhythms (DR) in gene expression in human oral mucosa: Implications for gender differences in toxicity, response and survival and optimal timing of targeted therapy (Rx). ASCO Meeting Abstracts 25 (2007) Abstract 2507